SP600125 (GMP)

Overview

SP600125 (GMP) is SP600125 ( HY-12041 ) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC 50 s of 40, 40 and 90 nM for JNK1 , JNK2 and JNK3 , respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .

Application

Products | Products > GMP Small Molecules | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Bladder Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cancer | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > JNK | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Ferroptosis

Product Information

• Catalog No.: HY-12041G
• CAS No.: 129-56-6
• Molecular Formula: C14H8N2O
• Molecular Weight: 220.23
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source